Lung - NSCLCTaken continuously — no infusion cycle8 effects documented
A daily targeted pill for EGFR-mutant lung cancer, usually well tolerated. The common effects are diarrhea and an acne-like rash (both early), plus dry skin and nail changes. Your team also monitors the heart (ECG/echo) and watches for uncommon lung inflammation.
Oral osimertinib taken once daily, continuously (an EGFR-targeted pill). Effects follow the classic EGFR-TKI skin sequence — rash EARLY (week 1-2), then dry skin, then nail changes later — and onset is measured in weeks-months, not infusion cycles. Rare but serious: heart-rhythm/heart-function changes and lung inflammation.
Get help straight away — this is true on any regimen, on any day.
A temperature of 100.4°F (38°C) or higher during treatment can mean a
serious infection while your blood counts are low. Call your team or go to the ER — do not
wait it out.
Also urgent: trouble breathing or chest pain · swelling of the face, lips or throat ·
new confusion or fainting · shaking chills · not being able to keep fluids down.
This is standing guidance shown to everyone. Nothing on this page is based on anything
about you, and nobody is monitoring you.
What is reported
This regimen is taken continuously, so effects are described in the terms their sources use rather than by cycle day.
Diarrhea
usually within the first 1-2 weeks; ongoing
Loose or frequent stools, usually starting in the first week or two. Anti-diarrheal medicine, hydration, and diet adjustments help; report if it's severe or persistent.
Call your team: More than 6 stools above normal in a day, or any with dizziness.
reported by about 58% of people; severe in 2.2% · from Osimertinib
Acneiform rash
first 1-2 weeks; peaks weeks 2-4
An acne-like rash on the face and upper body, typically appearing in the first 1-2 weeks — often a sign the drug is active. Gentle skin care, sun protection, and sometimes an antibiotic cream/tablet help; tell your team early.
Call your team: Widespread blistering/peeling, or a rash with skin-infection signs (pus, spreading redness).
reported by about 58% of people; severe in 1.1% · from Osimertinib
Dry skin
from ~weeks 2-4; builds over months
Dry, sometimes itchy or cracking skin that tends to build over the first weeks-months. Frequent moisturizing helps.
reported by about 36% of people; severe in 0.4% · from Osimertinib
Nail changes (paronychia)
delayed (after ~4-8 weeks); builds over months
Tender, red, sometimes infected skin around the nails that tends to appear later (after about a month) and builds over time. Antiseptic soaks and careful nail care help; tell your team if painful.
reported by about 35% of people; severe in 0.4% · from Osimertinib
Mouth sores (stomatitis)
often within the first few weeks; recurrent
Soreness or small ulcers in the mouth, often in the first few weeks. Gentle oral care and a bland diet help.
Call your team: Can't eat or drink because of mouth pain.
reported by about 32% of people; severe in 0.7% · from Osimertinib
Decreased appetite
Reduced appetite that can persist. Small, frequent, high-calorie meals and dietitian support help; report ongoing weight loss.
reported by about 20% of people; severe in 2.5% · from Osimertinib
Heart rhythm / heart function changes
can develop over months of daily dosing
Osimertinib can affect the heart's electrical timing (QTc) and, less often, weaken the heart's pumping. These are usually found on monitoring rather than felt. Your team does ECGs and may check an echocardiogram; report fainting, palpitations, or breathlessness.
Call your team urgently: Fainting, a fast/irregular heartbeat, or new breathlessness.
reported by about ~4 (reduced pumping); ~1 QTc>500ms% of people · from Osimertinib
Lung inflammation (interstitial lung disease)
any time during daily dosing
Uncommon but serious inflammation of the lungs, causing new or worsening cough, breathlessness, or fever. Report breathing changes promptly — the drug is stopped and the problem investigated.
Call your team urgently: New or worsening breathlessness, cough, or fever — contact your team urgently.
reported by about 4% of people · from Osimertinib
Where this comes from
S1. Osimertinib (Tagrisso) FDA label, first-line Table 8 = FLAURA (Soria, n=279) (2018) — PMID 29151359 / FDA label
A window appears here only where a retrievable document ties it to a drug in
this regimen. Where nothing could be found, the window was removed rather than estimated —
so a missing time is an honest gap, not an oversight.